Valence Discovery Announces $8.5 Million in Seed Funding to Scale AI-Based Generative Chemistry Engine and Collaborations with Leading Discovery Organizations

Valence Discovery, a leader in AI-first design of novel chemistry against previously intractable biology, announced today that it has closed an oversubscribed US$7 million seed financing. The financing, which was co-led by Fifty Years and Air Street Capital, with participation from Amplitude Ventures, Phoenix Venture Partners, and Abcam founder and former CEO, Jonathan Milner, adds to US$1.5 million raised previously, bringing Valence’s total seed funding to US$8.5 million. The new funds will support expanding Valence’s AI-based generative chemistry engine, scaling its partnerships with world-class discovery organizations, further building a leading team of interdisciplinary scientists, and advancing internal drug discovery efforts.

NewsGuest UserDecember 15, 2021Valence Discovery, AI

Valence Discovery Announces Multi-Target AI-Enabled Drug Design Collaboration with Servier

MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Valence Discovery (“Valence”), an emerging leader in AI-enabled drug design, announced today a multi-target discovery collaboration leveraging Valence’s platform for generative drug design with Servier, a global pharmaceutical company.

NewsGuest UserMarch 24, 2021Valence Discovery, Servier, Drug design, artificial intelligence